NEW YORK, NY, September 19, 2022 — Aetion
,
a global real-world evidence (RWE) technology and analytics provider and the
Crohn’s & Colitis Foundation
(Foundation), a non-profit organization dedicated to finding cures for Crohn’s disease and ulcerative colitis, announced a research collaboration that will use registry data to explore the potential value of high-priced inflammatory bowel disease (IBD) treatments, and identify patient characteristics that predict whether a patient will have progressive IBD that would be unlikely to respond to current treatments.
Advances in IBD treatments have led to improved clinical outcomes, yet questions around the value of these high-priced treatments remain. Moreover, some patients receiving these treatments may continue to experience worsening or progressive disease, thus demonstrating the need to better understand IBD disease progression while also ensuring patients are getting the most value from their respective treatment plans.
Aetion and the Foundation will collaborate on two separate research projects to address these concerns. The first project will focus on creating a model to predict which patients will have disease progression, and the second will explore how patient characteristics influence treatment patterns over time. Both projects will leverage real-world data from IBD Plexus
®
, the Foundation’s robust data driven IBD research network designed to capture a holistic picture of a patient’s disease.
“The Foundation has amassed a valuable dataset that captures patient experiences regarding IBD symptoms and vision for advancing treatment options.
IBD Plexus has opened a door for the Foundation to collaborate with the brightest scientific minds who are deeply committed to innovation,” said Angela Dobes, Vice President of IBD Plexus
®
, at the Foundation “By combining forces with Aetion, one of the most respected organizations in developing high-quality RWE, we are turning real-world data into evidence and insights that will ultimately help us create better, more tailored treatment options for IBD patients worldwide.”
“There is a lot of uncertainty regarding the clinical and economic value of newly approved IBD therapies, and this is where RWE built upon high-quality RWD can play a valuable role in filling evidence gaps,” said Ashley Jaksa, Market Access Scientific Strategy Lead, Aetion. “Aetion is thrilled to work with such a strong set of registry data to extract evidence and meaning for those examining the value of these treatments and developing new treatment options.”
Aetion and the Foundation expect to share results of the research projects in 2023. For more information about this partnership, please reach out to us at
info@aetion.com
, learn more about us at aetion.com, and follow us @aetioninc.